About Sang Lee

Sang Lee is the CEO of ABL Bio, a company specializing in bispecific antibodies. ABL Bio is developing various clinical and non-clinical assets based on its bispecific antibody platform 'Grabody'. The company recently entered an equity investment agreement with Eli Lilly and Company worth KRW 22 billion, with funds allocated to advance its core technologies and explore collaborative opportunities with Lilly. ABL Bio also has a U.S. subsidiary, Neok Bio, focused on bispecific antibody-drug conjugate (ADC) trials.

Resources Pricing

Resources

Join freeJoin for free Free · no credit card

Sign Out Dashboard

The Startup Fundraising Platform

Raise funds for your startup

Find the right investors and get real replies — instantly, powered by AI.

AI-scored pitch deck
Matched investor list
Personalized outreach drafts

Join for free

Takes 30 seconds · No credit card · Cancel anytime

See it in action ↓

Library
Articles
Pitch Decks
Videos
Shorts
Profiles
Visuals
Questions
Ask

All
Seed & Pre-Seed
Series A & B
Fintech
SaaS & Dev Tools
Consumer & Social
Marketplace & Frontier
Mistakes to Avoid
Checklist
How to Send
Design
Length
Order
Storytelling
Investor Q&A
One-Pager
Email Templates
Data Room
Investor Update
Term Sheet
SAFE vs Priced
Due Diligence
Timeline
Metrics
Valuation
Cap Table
Pipeline
Board
Objections
References
Closing
Bridge Round
Down Round
Secondary Sale
Investor Rejection
First Meeting
Second Meeting
Partner Meeting
Post-Mortem
Update Cadence
Angel Round
Option Pool Shuffle
Fundraise Pause
Vetting VCs
First 90 Days
First Board Meeting
Reference Calls
NDA Template
Bylaws Template

LibraryPitch Deck Examples

Slide-by-slide guide

Library
Articles
Pitch Decks
Videos
Shorts
Profiles
Visuals
Questions
Ask

LibraryArticles

•By Alejandro Cremades

Sang Lee, Founder of ABL Bio

About Sang Lee

Sang Lee at a glance

More founders in Seoul, South Korea (44)

Browse related founder lists (3)